• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Thoracic cancer. >Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non‐small cell lung cancer
【24h】

Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non‐small cell lung cancer

机译：单独用途化疗和免疫检查点抑制剂和免疫检查点抑制剂的组合比较治疗晚期和转移性非小细胞肺癌

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Single agent immune checkpoint inhibitors (ICIs) improve survival outcomes compared to chemotherapy for advanced non-small cell lung cancer (NSCLC), but treatment efficacy widely varies. The combination of ICIs with chemotherapy has shown promising efficacy over chemotherapy alone; however, whether this strategy is superior to single agent ICIs for the treatment of advanced NSCLC remains unknown. The records of 109 patients with advanced NSCLC who were administered at least one cycle of ICIs were retrospectively reviewed. Patients were grouped based on the presence or absence of a chemotherapy treatment combination. Efficacy and survival outcomes were analyzed. Sixty-nine (58.0%) patients received single agent ICIs (ICI group) and 50 (42.0%) received ICIs and chemotherapy (ICC group). The median (3.2 vs. 3.0?months; P?=?0.025) and one-year (34.5 vs. 9.6%; P?=?0.026) progression-free survival (PFS) rates were significantly better in the ICC than in the ICI group. The superior efficacy of ICC remained in the propensity score matched pairs (median PFS 3.2 vs. 2.6?months, P?=?0.032; 1-year PFS 35.2 vs. 7.6%; P?=?0.035). Eastern Cooperative Oncology Group performance status 0-1 (HR 0.37, 95% CI 0.22-0.62; P 0.001) and the ICC group (HR 0.56, 95% CI 0.34-0.94; P = 0.028) were predictive of PFS. Subgroup-to-chemotherapy interaction revealed improved risk reduction for adenocarcinoma and EGFR mutation. Combing chemotherapy with ICIs improved treatment efficacy over ICIs alone. The additional efficacy of chemotherapy may differ between histological subtypes and EGFR mutation status. ? 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
机译：单药物免疫检查点抑制剂（ICIS）与晚期非小细胞肺癌（NSCLC）的化疗相比，改善生存结果，但治疗疗效范围广泛变化。 ICIS与化疗的组合仅针对单独的化疗有前途的疗效;但是，该策略是否优于单一代理ICIS，用于治疗先进的NSCLC仍然未知。回顾性地审查了109名高级NSCLC患者的患者的记录。患者基于化疗治疗组合的存在或不存在进行分组。分析了疗效和生存结果。六十九（58.0％）患者接受单剂ICIS（ICI组）和50（42.0％）接受ICIS和化疗（ICC集团）。中位数（3.2与3.0？几个月; p？= 0.025）和一年（34.5与9.6％; p？= 0.026）进展的生存（PFS）率在ICC中显着更好地更好ICI集团。 ICC的卓越效果仍然在倾向得分匹配对（中位数PFS 3.2与2.6？月，P？= 0.032; 1年PFS 35.2与7.6％; P？= 0.035）。东方合作肿瘤组性能状态0-1（HR 0.37,95％CI 0.22-0.62; P <0.001）和ICC组（HR 0.56,95％CI 0.34-0.94; P = 0.028）是PFS的预测性。亚组来的化疗相互作用揭示了腺癌和EGFR突变的改善风险降低。用ICIS梳理化疗改善了ICIS的治疗效果。化学疗法的额外疗效可能在组织学亚型和EGFR突变状态之间不同。 ？ 2019年的作者。中国肺部肿瘤集团和约翰瓦里和儿子澳大利亚发表的胸癌

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号